ACC.26 advanced registration ends Feb. 12 – register now!

David Preiss, MB ChB, PhD

General Statement of Disclosure:

RESEARCH/RESEARCH GRANTS: Boehringer Ingelheim Pharmaceuticals, Inc(NONE), Novartis Corporation(NONE), Novo Nordisk Inc.(NONE), Mylan(NONE)

View Full Disclosure